XTL Biopharmaceuticals Ltd. (XTLB)
$1.06
+0.01 (+0.95%)
Rating:
Recommendation:
Buy
| Symbol | XTLB |
|---|---|
| Price | $1.06 |
| Beta | 0.953 |
| Volume Avg. | 0.00M |
| Market Cap | 5.776M |
| Shares () | - |
| 52 Week Range | 0.75-1.54 |
| 1y Target Est | - |
| DCF Unlevered | XTLB DCF -> | |
|---|---|---|
| DCF Levered | XTLB LDCF -> | |
| ROE | -111.94% | Strong Sell |
| ROA | -129.25% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -2.65 | Sell |
| P/B | 230.95 | Strong Buy |
Latest XTLB news
About
Download (Excel)XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.